Description

n-[3-([4,5'-Bipyrimidin]-2-Ylamino)-4-Methylphenyl]-4-[[(3S)-3-(Dimethylamino)-1-Pyrrolidinyl]Methyl]-3-(Trifluoromethyl)-Benzamide, (Hcl Salt) CAS NO 859212-17-2 is a high-purity, non-nucleoside reverse transcriptase inhibitor (NNRTI) intermediate with a complex heterocyclic structure. This compound is critical for pharmaceutical research and development, particularly in the synthesis of next-generation antiviral therapeutics. It is primarily sought by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the development of treatments for viral infections.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) for antiviral drug discovery.
• Antiviral Research: Used as a reference standard and active scaffold in biochemical assays and structure-activity relationship (SAR) studies targeting HIV and other retroviruses.
• Medicinal Chemistry: Serves as a sophisticated precursor for the development of new chemical entities (NCEs) with potential therapeutic applications.
• Process Development: Employed in the optimization of scalable synthetic routes for active pharmaceutical ingredients (APIs) in pilot and commercial manufacturing.
• Contract Research Organizations (CROs): Utilized in custom synthesis projects and preclinical development studies for client-specific drug candidates.

Basic Information

Product Name	n-[3-([4,5'-Bipyrimidin]-2-Ylamino)-4-Methylphenyl]-4-[[(3S)-3-(Dimethylamino)-1-Pyrrolidinyl]Methyl]-3-(Trifluoromethyl)-Benzamide, (Hcl Salt)
CAS No.	859212-17-2
Molecular Formula	C31H33F3N8O • HCl
Molecular Weight	638.10 g/mol (free base)
Synonyms	BMS-488043 Intermediate; 859212-17-2; BMS 488043 HCl Salt Precursor; 4-[[(3S)-3-(Dimethylamino)-1-pyrrolidinyl]methyl]-N-[3-[(4,5'-bipyrimidin-2-yl)amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide hydrochloride; BMS-488043 Related Compound; NNRTI Intermediate; Antiviral Intermediate A; Benzamide, 4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-[3-[(4,5'-bipyrimidin-2-yl)amino]-4-methylphenyl]-3-(trifluoromethyl)-, hydrochloride (1:1)
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to strict quality management systems. Each batch is characterized and tested using advanced analytical techniques including HPLC, NMR, and LC-MS to ensure identity, purity, and consistency. A comprehensive Certificate of Analysis (COA) detailing all specifications is provided with every shipment. We support development under cGMP guidelines as required for preclinical and clinical stage materials.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and should be handled under dry conditions to maintain stability. For long-term storage, consider desiccants or an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.